Skip to main content

Table 3 Disease activity (measured by the DAS28) and EULAR-disease activity classification percentages during one infusion interval

From: Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

 

Prior to

infusion

50% of the

infusioninterval

75% of the

infusioninterval

100% of the

infusioninterval

Mean DAS28 (± SD)

3.3 (± 1.1)

3.0 (± 1.0)

3.4 (± 1.1)

3.4 (± 1.1)

Patients in remission (n, %)

7 (26%)

10 (37%)

6 (22%)

8 (30%)

Patients with low disease activity (n, %)

6 (22%)

6 (22%)

6 (22%)

3 (11%)

Patients with moderate disease activity (n, %)

11 (41%)

11 (41%)

14 (52%)

15 (56%)

Patients with high disease activity (n, %)

3 (11%)

0 (0%)

1 (4%)

1 (4%)